This proposal provides a comprehensive plan for the career development of the applicant in cancer biomarker discovery and validation. Through mentored research, coursework and independent study, Dr. Van Poznak will develop collaborative relationships and methodologic skills to support her research agenda in pharmogenomics and toxicities of therapy. The didactic training in clinical trial design and ethics, pharmacogenomics and genetic analysis proposed will greatly expand the candidate's current training and research program. This proposal focuses on the use of novel technologies to improve assessment of risk of toxicities during cancer care, specifically by combining clinical and genetic data to establish an individualized patient specific profile of risk for developing osteonecrosis of the jaw (ONJ), an oral lesion with exposed, necrotic bone. These lesions are often associated with pain, swelling, and infection. ONJ may occur in 1- 10% of patients with cancer and bone metastases treated with intravenous nitrogen containing bisphosphonate therapy. The bisphosphonates decrease the risk of skeletal related events, such as fracture, by approximately one third and are routinely used in patients with cancer involving the bone. The overarching goal of this research proposal is to develop an index for estimating an individual's risk of developing ONJ. This index of risk will be created with the data generated from a multi-Institutional, Case Control study investigating single nucleotide polymorphisms (SNPs) within the target enzyme of the bisphosphonates, as well as investigate clinical and epidemiologic features associated with ONJ in patients with metastatic bone disease who have received intravenous bisphosphonate therapy. The identification of clinical and genetic markers correlated with risk of toxicity will lend insight into the etiology of ONJ and will provide patients and their health care providers a tool to assess risks of therapy on an individualized basis. The didactic training and mentored research activities will provide Dr Van Poznak the foundation for which she can generate highly competitive grant applications in the final years of the award and advance patient care through personalized medicine as it relates to cancer and the maintenance of bone integrity.
Public Health: The constellation of clinical, epidemiologic and genetic factors will be used to generate an index of risk for the likelihood of developing osteonecrosis of the jaw (ONJ). Patients, dentists and medical oncologists will benefit from an instrument that will provide a personalized ONJ risk assessment.
|Choksi, Palak; Williams, Margaret E; Kidwel, Kelley M et al. (2016) Adjuvant Aromatase Inhibitors in Early Breast Cancer May Not Increase the Risk of Falls. J Bone Rep Recomm 2:|
|Taichman, L Susan; Inglehart, Marita R; Giannobile, William V et al. (2015) Periodontal Health in Women With Early-Stage Postmenopausal Breast Cancer Newly on Aromatase Inhibitors: A Pilot Study. J Periodontol 86:906-16|
|Hertz, Daniel L; Kidwell, Kelley M; Thibert, Jacklyn N et al. (2015) Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses. Mol Oncol 9:1868-76|
|Taichman, L Susan; Gomez, Grace; Inglehart, Marita Rohr (2015) Oral Health-Related Complications of Breast Cancer Treatment: Assessing Dental Hygienists' Knowledge and Professional Practice. J Dent Hyg 89 Suppl 2:22-37|
|Taichman, L Susan; Gomez, Grace; Inglehart, Marita Rohr (2014) Oral health-related complications of breast cancer treatment: assessing dental hygienists' knowledge and professional practice. J Dent Hyg 88:100-13|
|Choksi, Palak; Williams, Margaret; Clark, Patricia M et al. (2013) Skeletal manifestations of treatment of breast cancer. Curr Osteoporos Rep 11:319-28|
|Taichman, L Susan; Havens, Aaron M; Van Poznak, Catherine H (2013) Potential implications of adjuvant endocrine therapy for the oral health of postmenopausal women with breast cancer. Breast Cancer Res Treat 137:23-32|
|Roop, Ryan P; Naughton, Michael J; Van Poznak, Catherine et al. (2013) A randomized phase II trial investigating the effect of platelet function inhibition on circulating tumor cells in patients with metastatic breast cancer. Clin Breast Cancer 13:409-15|
|Rae, James M; Regan, Meredith M; Thibert, Jacklyn N et al. (2013) Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J Natl Cancer Inst 105:1332-4|
|Taxel, Pamela; Choksi, Palak; Van Poznak, Catherine (2012) The management of osteoporosis in breast cancer survivors. Maturitas 73:275-9|
Showing the most recent 10 out of 17 publications